Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 22 of 59, showing 10 Applications out of 584 total, starting on record 211, ending on 220

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

211.

ECCT/24/06/01   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Raymond Scott McClelland
Site(s) in Kenya
1. Pwani Research Centre (Mombasa county)
 
02-07-2024 View

212.

ECCT/24/06/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Charity Wambui Kanyoro
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
28-07-2024 View

213.

ECCT/24/07/05   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Bernhards Ogutu
Site(s) in Kenya
1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county)
 
20-08-2024 View

214.

ECCT/24/10/02   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Center (Kericho county)
 
12-11-2024 View

215.

ECCT/24/03/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Prof Walter Godfrey Jaoko
Site(s) in Kenya
1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
25-04-2024 View

216.

ECCT/23/11/02   CROSSWALK Acute (A)
    A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. In this submission: International Cancer Institute (Uasin Gishu county)
 
11-01-2024 View

217.

ECCT/24/10/01   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Videlis Nduba Nzioka
Site(s) in Kenya
1. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
2. Clinical Research Health Network (CREA-N) (Machakos county)
3. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
4. KEMRI-Mtwapa Clinical Annex (Kilifi county)
5. University of Nairobi Clinical Research Centre (Nairobi City county)
 
21-12-2024 View

218.

ECCT/23/07/03   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Professor Videlis Nduba
2. Professor Videlis Nduba
Site(s) in Kenya
1. KENYA MEDICAL RESEARCH INSTITUTE-CENTRE FOR RESPIRATORY DISEASE RESEARCH (CRDR) (Nairobi City county)
2. KEMRI/CRDR, Siaya Clinical Research Annex (Siaya county)
3. Clinical Research Health Network (CREA-N) (Machakos county)
4. KEMRI-Mtwapa Clinical Annex (Kilifi county)
5. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
6. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
7. University of Nairobi Clinical Research Centre (Nairobi City county)
 
19-11-2023 View

219.

ECCT/23/08/01   ARNASA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Dr Teresa Kinyari
Site(s) in Kenya
1. University of Nairobi Clinical Research Centre (Nairobi City county)
2. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
3. Clinical Research Health Network (CREA-N) (Machakos county)
4. KEMRI-CRDR Siaya Clinical Research Annex (Siaya county)
5. KEMRI-Mtwapa Clinical Annex (Kilifi county)
6. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
06-12-2023 View

220.

ECCT/26/02/03   REVIVE Study - KNH
    A randomised, double blinded, placebo-controlled, multicentre trial of azithromycin prophylaxis for advanced HIV disease   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (KNH) (Nairobi City county)
 
28-09-2026 View